ATE458735T1 - Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs - Google Patents

Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs

Info

Publication number
ATE458735T1
ATE458735T1 AT04776639T AT04776639T ATE458735T1 AT E458735 T1 ATE458735 T1 AT E458735T1 AT 04776639 T AT04776639 T AT 04776639T AT 04776639 T AT04776639 T AT 04776639T AT E458735 T1 ATE458735 T1 AT E458735T1
Authority
AT
Austria
Prior art keywords
pyridino
compounds
pyrimidine
cancer agent
alone
Prior art date
Application number
AT04776639T
Other languages
English (en)
Inventor
Weibo Wang
Ryan N Constantine
Liana M Lagniton
Sabina Pecchi
Matthew T Burger
Manoj C Desai
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE458735T1 publication Critical patent/ATE458735T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04776639T 2003-06-20 2004-06-17 Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs ATE458735T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48018003P 2003-06-20 2003-06-20
PCT/US2004/019158 WO2004113335A2 (en) 2003-06-20 2004-06-17 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents

Publications (1)

Publication Number Publication Date
ATE458735T1 true ATE458735T1 (de) 2010-03-15

Family

ID=33539266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776639T ATE458735T1 (de) 2003-06-20 2004-06-17 Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs

Country Status (15)

Country Link
US (1) US7326711B2 (de)
EP (1) EP1636225B1 (de)
JP (1) JP2007520435A (de)
KR (1) KR20060069356A (de)
CN (1) CN1809563A (de)
AT (1) ATE458735T1 (de)
AU (1) AU2004249730A1 (de)
CA (1) CA2528771A1 (de)
DE (1) DE602004025698D1 (de)
ES (1) ES2339862T3 (de)
IL (1) IL172192A0 (de)
MX (1) MXPA05013142A (de)
PT (1) PT1636225E (de)
TW (1) TW200503719A (de)
WO (1) WO2004113335A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156304A0 (en) * 2000-12-11 2004-01-04 Tularik Inc Cxcr3 antagonists
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
DK1601673T3 (da) * 2003-03-07 2009-08-24 Astrazeneca Ab Kondenserede heterocykler og anvendelser af disse
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
JP2007523955A (ja) * 2004-02-25 2007-08-23 ラ ホヤ ファーマシューティカル カンパニー 疾患の治療のためのアミンおよびアミド
ES2318478T3 (es) 2004-04-06 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Inhibidores de quinesina mitotica.
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
BRPI0513513A (pt) * 2004-07-22 2008-05-06 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
MX2007001953A (es) 2004-08-18 2007-05-09 Astrazeneca Ab Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
EP1778669A2 (de) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase-inhibitoren
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
CN101198596A (zh) * 2005-04-14 2008-06-11 诺华疫苗和诊断公司 作为hsp90抑制剂用于治疗增殖疾病的2-氨基-喹唑啉-5-酮
ATE474829T1 (de) 2005-06-27 2010-08-15 Amgen Inc Entzündungshemmende arylnitrilverbindungen
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
BRPI0806264A2 (pt) 2007-01-05 2011-08-30 Novartis Ag derivados ciclizados como inibidores de eg-5
PL2448938T3 (pl) * 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2558463A1 (de) 2010-04-14 2013-02-20 Incyte Corporation Kondensierte derivate als i3-hemmer
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102131612B1 (ko) 2011-09-02 2020-07-08 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
KR102137087B1 (ko) 2012-02-10 2020-07-24 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
CA2865957C (en) 2012-03-01 2020-02-11 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CN104470909B (zh) 2012-03-23 2018-04-24 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
JP6847851B2 (ja) * 2015-04-15 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
EP3298017B1 (de) * 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Verbindungen zur behandlung von spinaler muskelatrophie
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
MX2021001091A (es) 2015-12-10 2022-04-26 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
CA3043755A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
CA3065547A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
BR112019027719A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
CN108191860B (zh) * 2018-02-12 2019-12-10 中国医科大学 一种HIF-2α小分子抑制剂及其用途
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
EP3814360A1 (de) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroarylverbindungen zur behandlung von morbus huntington
JP7421507B2 (ja) 2018-06-27 2024-01-24 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3639593B2 (ja) 1993-05-31 2005-04-20 科研製薬株式会社 塩基性線維芽細胞増殖因子含有架橋ゼラチンゲル製剤
GB2307177A (en) 1995-11-15 1997-05-21 Agrevo Uk Ltd Fungicidal pyridopyrimidines
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
EP1226129B1 (de) 1999-10-27 2006-05-24 Cytokinetics, Inc. Chinazolinone benutzende verfahren und zusammenstellungen
IL156304A0 (en) 2000-12-11 2004-01-04 Tularik Inc Cxcr3 antagonists
EP1379554A2 (de) * 2001-02-21 2004-01-14 Curagen Corporation Proteine, dafür codierende polynukleotide und methoden unter verwendung davon
AU2002363429B2 (en) * 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002364128B2 (en) * 2001-12-06 2008-03-06 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
ATE447577T1 (de) * 2001-12-06 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
EP1594849A4 (de) * 2003-01-17 2007-07-04 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren

Also Published As

Publication number Publication date
US20050085490A1 (en) 2005-04-21
US7326711B2 (en) 2008-02-05
MXPA05013142A (es) 2006-03-17
CA2528771A1 (en) 2004-12-29
PT1636225E (pt) 2010-05-03
JP2007520435A (ja) 2007-07-26
EP1636225A2 (de) 2006-03-22
CN1809563A (zh) 2006-07-26
EP1636225B1 (de) 2010-02-24
WO2004113335A3 (en) 2005-03-24
ES2339862T3 (es) 2010-05-26
AU2004249730A1 (en) 2004-12-29
IL172192A0 (en) 2006-04-10
TW200503719A (en) 2005-02-01
WO2004113335A2 (en) 2004-12-29
DE602004025698D1 (de) 2010-04-08
KR20060069356A (ko) 2006-06-21

Similar Documents

Publication Publication Date Title
ATE458735T1 (de) Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
TW200728304A (en) 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones
WO2004006859A3 (en) Platinum compound
FR13C0062I1 (de)
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
TW200718689A (en) 2-Amino-quinazolin-5-ones
MY148583A (en) Pyridine [3,4-b] pyrazinones
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
WO2006130607A3 (en) Controlled-release formulation useful for treating disorders associated with hepatitis c virus
TW200716628A (en) Novel compounds
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
WO2009143156A3 (en) Imidazo [1, 2-a] pyridine compounds as gaba-a receptor modulators
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2002028860A3 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
UA93522C2 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina
MX2012012531A (es) Derivado de imidazo [1, 2-a] piridina.
DE60214412D1 (de) Simplifizierte sarcodictyn-derivate als anti-tumor-mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties